Therapeutic landscape for ulcerative colitis: Where is the adacolumn® system and where should it be?

Clinical and Experimental Gastroenterology

Volumn 6, Issue 1, 2013, Pages 1-7

  Vecchi, Maurizio ^a   Vernia, Piero ^b   Riegler, Gabriele ^c   D'Incà, Renata ^d   Annese, Vito ^e   Bagnoli, Siro ^e  

^a UNIVERSITY OF MILAN   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

^e CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

Apheresis; Guidelines; Inflammatory bowel disease; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; MESALAZINE; STEROID;

ADVERSE OUTCOME; APHERESIS; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; FATIGUE; FEVER; GRANULOCYTE MONOCYTE APHERESIS; HEADACHE; HEALTH CARE COST; HEMATOLOGY EQUIPMENT; HOT FLUSH; HUMAN; HYPERTRANSAMINASEMIA; LEUKAPHERESIS; LEUKOPENIA; META ANALYSIS (TOPIC); NAUSEA; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT SAFETY; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SHIVERING; SYSTEMATIC REVIEW; THERAPY EFFECT; TIME TO TREATMENT; ULCERATIVE COLITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 84872694547     PISSN: None     EISSN: 11787023     Source Type: Journal    
DOI: 10.2147/CEG.S33275     Document Type: Review

References (55)

1. Dignass A, Van Assche G, Lindsay JO, et al; For the European Crohn's and Colitis Organisation (ECCO). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
2. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365: 1713-1725.
3. De Silva S, Devlin S, Panaccione R. Optimizing the safety of biologic therapy for IBD. Nat Rev Gastroenterol Hepatol. 2010;7:93-101.
4. Lichtenstein GR, Rutgeerts P, Sandborn WJ, et al. A pooled analysis of infections, malignancy, and mortality in infliximab- and immunomodulatortreated adult patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107:1051-1063.
5. Fujimori J, Yoshino S, Koiwa M, et al. Improvement in rheumatoid arthritis following application of an extracorporeal granulotrap column, G-1. Rheumatol Int. 1996;15:175-180.
6. Shimoyama T, Sawada K, Tanaka T. Granulocyte and monocyte apheresis with the G-1 column in the treatment of patients with active ulcerative colitis. Jpn I Apher. 1999;18:117-131.
7. Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher. 2001;16:1-9.
8. Hanai H, Watanabe F, Takeuchi K, et al. Leukocyte adsorptive apheresis for the treatment of active ulcerative colitis: a prospective, un-controlled, pilot study. Clin Gastroenterol Hepatol. 2003;1:28-35.
9. Hanai H, Watanabe F, Yamada M, et al. Adsorptive granulocyte and monocyte apheresis versus prednisolone in patients with corticosteroid-dependent moderately severe ulcerative colitis. Digestion. 2004;70:36-44.
10. Naganuma M, Funakoshi S, Sakuraba AR, et al. Granulocytapheresis is useful as an alternative therapy in patients with steroid-refractory or -dependent ulcerative colitis. Inflamm Bowel Dis. 2004;10:251-257.
11. Yamamoto T, Umegae S, Kitagawa T, et al. Granulocyte and monocyte adsorptive apheresis in treatment of active distal ulcerative colitis: a prospective, pilot study. Aliment Pharmacol Ther. 2004;20:783-792.
12. Kanke K, Nakano M, Hiraishi H, Terano A. Clinical evaluation of granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liver Dis. 2004;36:811-817.
13. Saniabadi AR, Hanai H, Suzuki Y, et al. Adacolumn for selective leu kocytapheresis as a non-pharmacological treatment for patients with disorders of the immune system: an adjuvant or an alternative to drug therapy? J Clin Apher. 2005;20:171-184.
14. Sandborn WJ. Preliminary data on the use of the apheresis in inflam matory bowel disease. Inflamm Bowel Dis. 2006;12 Suppl 1:15-21.
15. Caprilli R, D'Ovidio V. Leukocytapheresis as promising therapy for inflammatory bowel disease. Dig Liver Dis. 2007;39:435-437.
16. Domènech E, Hinojosa J, Esteve-Comas, et al. Granulocytaphaeresis in steroid-dependent inflammatory bowel disease: a prospective, open, pilot study (GETECCU). Aliment Pharmacol Ther. 2004;20:1347-1352.
17. Bresci G, Parisi G, Mazzoni A, Scatena F, Capria A. Treatment of patients with acute ulcerative colitis: conventional corticosteroid therapy (MP) versus granulocytapheresis (GMA): a pilot study. Dig Liver Dis. 2007;39: 430-434.
18. Kruis W, Dignass A, Steinhagen-Thiessen E, et al. Open label trial of granu locyte apheresis suggests therapeutic efficacy in chronically active steroid-refractory ulcerative colitis. World J Gastroenterol. 2005;11:7001-7006.
19. Ljung T, Thomsen OO, Vatn M, et al. Granulocyte. Monocyte/macrophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol. 2007;42:221-227.
20. Habermalz B, Sauerland S. Clinical effectiveness of selective granu locyte, monocyte adsorptive apheresis with the Adacolumn device in ulcerative colitis. Dig Dis Sci. 2010;55:1421-1428.
21. Nakamura T, Kawagoe Y, Matsuda T, et al. Effect of granulocyte and monocyte adsorption apheresis on urinary albumin excretion and plasma endothelin-1 concentration in patients with active ulcerative colitis. Blood Purif. 2004;22:499-504.
22. Hanai H, Iida T, Takeuchi K, et al. Intensive granulocyte and monocyte adsorption versus intravenous prednisolone in patients with severe ulcerative colitis: an unblinded randomised multi-centre controlled study. Dig Liver Dis. 2008;40:433-440.
23. Maiden L, Takeuchi K, Baur R, et al. Selective white cell apheresis reduces relapse rates in patients with IBD at significant risk of clinical relapse. Inflamm Bowel Dis. 2008;14:1413-1418.
24. Sands B, Sandborn WJ, Feagan B, et al. A randomized, double-blind, sham-controlled study of granulocyte/monocyte apheresis for active ulcerative colitis. Gastroenterology. 2008;135:400-409.
25. Tanaka T, Okanobu H, Yoshimi S, et al. In patients with ulcerative colitis, adsorptive depletion of granulocytes and monocytes impacts mucosal level of neutrophils and clinically is most effective in steroid naïve patients. Dig Liver Dis. 2008;40:731-736.
26. +CD16 DR monocytes in patients with inflammatory bowel disease. Am J Gastroenterol. 2008;103:1210-1216.
27. Kashiwagi N, Hirata I, Kasukawa R. A role for granulocyte and monocyte apheresis in RA treatment. Ther Apher. 1998;2:134-141.
28. Matsuda R, Koide T, Tokoro C, et al. Quantitative cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naive ulcerative colitis during active and quiescent disease. Inflamm Bowel Dis. 2009;15:328-334.
29. Cuadrado E, Alonso M, de Juan Echaniz P, Arenas JI. Regulatory T cells in patients with inflammatory bowel diseases treated with Adacolumn granulocytapheresis. World J Gastroenterol. 2008;14:1521-1527.
30. Waitz G, Petermann S, Liebe S, Emmrich J, Ramlow W. Reduction of dendritic cells by granulocyte and monocyte adsorption apheresis in patients with ulcerative colitis. Dig Dis Sci. 2008;53:2507-2515.
31. Hanai H. Position of selective leukocytapheresis in the medical therapy of ulcerative colitis. World J Gastroenterol. 2006;47:7568-7577.
32. Shimada M, Iwase H, Tsuzuki T, et al. A pilot study of leukocytapheresis efficacy with 1.5 liter blood processing volume in patients with ulcerative colitis. Ther Apher Dial. 2008;12:368-373.
33. Mitsuyama K, Sata M. Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action. Cytotherapy. 2009;11:229-237.
34. Hibi T, Ameshima Y, Sekiguchi Y, et al. Treating ulcerative colitis by Adacolumn therapeutic leucocytapheresis: clinical efficacy and safety based on surveillance of 656 patients in 53 centres in Japan. Dig Liver Dis. 2009;41:570-577.
35. Ljung T, Thomsen OO, Vatn M, et al. Granulocyte, monocyte/mac rophage apheresis for inflammatory bowel disease: the first 100 patients treated in Scandinavia. Scand J Gastroenterol. 2007;42:221-227.
36. Yamamoto T, Umegae S, Matsumoto K. Mucosal healing in patients with ulcerative colitis during a course of selective leukocytapheresis therapy: a prospective cohort study. Inflamm Bowel Dis. 2010;16:1905-1911.
37. Sakata Y, Iwakiri R, Amemori S, et al. Comparison of the efficacy of granulocyte and monocyte/macrophage adsorptive apheresis and leukocytapheresis in active ulcerative colitis patients: a prospective randomized study. Eur J Gastroenterol Hepatol. 2008;20:629-633.
38. Sawada K, Kusugami K, Suzuki Y, et al. Leukocytapheresis in ulcerative colitis: results of a multicenter double-blind prospective case-control study with sham apheresis as placebo treatment. Am J Gastroenterol. 2005;100:1362-1369.
39. Cabriada JL, Ibargoyen N, Hernández A, Bernal A, Castiella A. Sustained remission after steroids and leukocytapheresis induced response in steroid-dependent ulcerative colitis: results at 1 year. Dig Liver Dis. 2010;42:432-435.
40. Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104:2990-2995.
41. Yamamoto T, Satoru U, Matsumoto K. Daily granulocyte and monocyte adsorptive apheresis in patients with active ulcerative colitis: a prospective safety and feasibility study. J Gastroenterol. 2011;46:1003-1009.
42. Dignass AU, Eriksson A, Kilander A, Pukitis A, Rhodes JM, Vavricka S. Clinical trial: five or ten cycles of granulocyte-monocyte apheresis show equivalent efficacy and safety in ulcerative colitis. Aliment Pharmacol Ther. 2010;31:1286-1295.
43. Yamamoto T, Saniabadi AR, Maruyama Y, Umegae S, Matsumoto K. Factors affecting clinical and endoscopic efficacies of selective leucocytapheresis for ulcerative colitis. Dig Liver Dis. 2007;39: 626-633.
44. D'Ovidio V, Bresci G, Principi B, et al. Long term efficacy of granu locyte-monocyte apheresis in ulcerative colitis: The Italian Registry of therapeutic apheresis. J Crohns Colitis. 2010;4:s72.
45. Suzuki Y, Yoshimura N, Saniabadi AR, Saito Y. Selective granulocyte and monocyte apheresis as a first-line treatment for steroid naive patients with active ulcerative colitis: a prospective uncontrolled study. Dig Dis Sci. 2004;49:565-571.
46. Kim HJ, Kim JS, Han DS, et al. Granulocyte and monocyte adsorption apheresis in Korean conventional treatment-refractory patients with active ulcerative colitis: a prospective open label multicenter study. Korean J Gastroenterol. 2005;45:34-44.
47. Yamamoto T, Umegae S, Matsumoto K. Safety and clinical efficacy of granulocyte and monocyte adsorptive apheresis therapy for ulcerative colitis. World J Gastroenterol. 2006;12:520-525.
48. Tomomasa T, Kobayashi A, Kaneko H, et al. Granulocyte adsorptive apheresis for pediatric patients with ulcerative colitis. Dig Dis Sci. 2003;48:750-754.
49. Mori K, Yoshihara T, Ando T, et al. Cytapheresis therapy for ulcer ative colitis in three pediatric patients. J Pediatr Gastroenterol Nutr. 2004;39:549-551.
50. Kawasaki Y, Suzuki J, Suzuki S, Suzuki H. Leukocytapheresis with leukocyte removal filter for severe ulcerative colitis in childhood. J Pediatr Gastroenterol Nutr. 2004;39:422-425.
51. Ikeda H, Ishumaru Y, Takayasu H, et al. Efficacy of granulocyte apheresis in pediatric patients with ulcerative colitis: a pilot study. J Pediatr Gastroenterol Nutr. 2006;43:592-596.
52. Martin de Carpi J, Vilar P, Prieto G, García Novo MD, Ribes C, Varea V. Safety and efficacy of granulocyte and monocyte adsorption apheresis in pediatric inflammatory bowel disease: a prospective pilot study. J Pediatr Gastroenterol Nutr. 2008;46:386-391.
53. Ruuska T, Wever V, Lindgren F, et al. Granulocyte-monocyte adsorptive apheresis in pediatric inflammatory bowel disease: results, practical issues, safety and future perspectives. Inflamm Bowel Dis. 2009;15:1049-1054.
54. Panes J, Guilera M, Ginard D, et al. Treatment cost of ulcerative colitis: is apheresis with Adacolumn cost-effective? Dig Liver Dis. 2007;39: 617-625.
55. Persson U, Borg S, Hjelmgren. Economic evaluation of Adacolumn apheresis for treatment of patients with moderate to severe Crohn's disease or ulcerative colitis. Presented at the International Society for Pharmacoeconomics and Outcomes Research 8th Annual European Congress, November 6-8, 2005, Florence, Italy.